About: Effects of Methylprednisolone Pulse Therapy on Refractory Mycoplasma pneumoniae Pneumonia in Children

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effects of Methylprednisolone Pulse Therapy on Refractory Mycoplasma pneumoniae Pneumonia in Children Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Effects of Methylprednisolone Pulse Therapy on Refractory Mycoplasma pneumoniae Pneumonia in Children
Creator	Lee, Jae Kil, Hong Jwa, Hye Yang, Eun You, Sun
topic	covid:d240c3f69f1c35702fea557f7a5436717be14cd3#this
Source	Medline; PMC
abstract	PURPOSE: Mycoplasma pneumoniae (M. pneumoniae) is one of the most common causes of community-acquired pneumonia in children. The clinical course is typically self-limited and benign; however, rare cases of severe pneumonia can develop despite appropriate antibiotic therapy. We studied the effects of methylprednisolone pulse therapy on severe refractory M. pneumoniae pneumonia in children. METHODS: The clinical effects of methylprednisolone therapy were evaluated retrospectively in 12 children with severe refractory M. pneumoniae pneumonia, which was diagnosed serologically. All patients developed respiratory distress, high fever, and initial lobar pneumonic consolidation based on radiological findings. All clinical symptoms deteriorated despite appropriate antibiotic therapy. Thus, children were treated with intravenous methylprednisolone pulse therapy in addition to antibiotics. RESULTS: The average febrile period before admission was 4.9±1.7 days, and fever persisted in all children until steroid administration. Methylprednisolone pulse therapy (30 mg/kg) was given 5.4±2.5 days after admission. After methylprednisolone pulse therapy, clinical symptoms improved in all patients without adverse events. The fever subsided 0-2 h after initiation of corticosteroid therapy. The abnormal radiological findings resolved within 2.6±1.3 days, and the high C-reactive protein levels (6.7±5.9 mg/dL) on admission decreased to 1.3±1.7 mg/dL within 3.0±1.1 days after starting corticosteroid therapy. CONCLUSIONS: Three-day methylprednisolone pulse therapy could be applied to treatment of refractory M. pneumoniae pneumonia despite appropriate antibiotic therapy and appeared to be efficacious and well-tolerated.
has issue date	2013-11-15(xsd:dateTime)
bibo:doi	10.4168/aair.2014.6.1.22
bibo:pmid	24404389
has license	cc-by-nc
sha1sum (hex)	d240c3f69f1c35702fea557f7a5436717be14cd3
schema:url	https://doi.org/10.4168/aair.2014.6.1.22
resource representing a document's title	Effects of Methylprednisolone Pulse Therapy on Refractory Mycoplasma pneumoniae Pneumonia in Children
has PubMed Central identifier	PMC3881395
has PubMed identifier	24404389
schema:publication	Allergy Asthma Immunol Res
resource representing a document's body	covid:d240c3f69f1c35702fea557f7a5436717be14cd3#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/d240c3f69f1c35702fea557f7a5436717be14cd3
is schema:about of	named entity 'fulminant' named entity 'severe' named entity 'presented' named entity 'intervals' named entity 'complications' named entity 'bronchiolitis obliterans' named entity 'Pneumonia' covid:arg/d240c3f69f1c35702fea557f7a5436717be14cd3 named entity 'age' named entity 'peaked' named entity 'young adults' named entity 'severe' named entity 'high' named entity 'M. pneumoniae' named entity 'Mycoplasma pneumoniae' named entity 'M. pneumoniae' named entity 'acute respiratory distress syndrome' named entity 'M. pneumoniae' named entity 'young adults' named entity 'clinical features' named entity 'M. pneumoniae' named entity 'Methylprednisolone' named entity 'M. pneumoniae' named entity 'intravenous' named entity 'secretion' named entity 'immune responses' named entity 'immune status' named entity 'macrolide resistance' named entity 'IgM' named entity 'mutation' named entity 'clarithromycin' named entity 'cold agglutinin' named entity 'interleukin-1β' named entity 'infection' named entity 'gene' named entity 'immune-suppressive' named entity 'respiratory epithelium' named entity 'methylprednisolone' named entity 'alveolar' named entity 'serum samples' named entity 'refractory' named entity 'prospective study' named entity 'IgM' named entity 'roid' named entity 'animal study' named entity 'oral antibiotics' named entity 'lung' named entity 'febrile' named entity 'anti-inflammatory' named entity 'reverse transcription-polymerase chain reaction' named entity 'rRNA' named entity 'macrolide' named entity 'Chungnam National University' named entity 'immunocompromised host' named entity 'beats per minute' named entity 'RT-PCR' named entity 'respiratory distress' named entity 'proinflammatory cytokines' named entity 'antibiotic therapy' named entity 'aminotransferase' named entity 'pneumonia' named entity 'pleural effusion' named entity 'methylprednisolone' named entity 'CRP' named entity 'Thoracentesis' named entity 'corticosteroids' named entity '1:64' named entity 'corticosteroid therapy' named entity 'lymphocytes' named entity 'infection' named entity 'ANOVA' named entity 'follow-up' named entity 'M. pneumonia' named entity 'M. pneumoniae' named entity 'M. pneumoniae'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software